Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients
The study will draw patients from the Transplant Dermatology specialty clinic, where the investigators see organ transplant recipients (OTR) for regular screening and serve as a regional referral center for this population. Enrollment will be limited to 20 patients. Inclusion criteria are organ transplant recipients status, active immunosuppression for at least 5 years, and history of at least one NMSC.
NCT02751151 — Nonmelanoma Skin Cancers
Status: Completed
http://inclinicaltrials.com/nonmelanoma-skin-cancers/NCT02751151/
A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma
This phase 1-2 trial studies how well pembrolizumab with or without vismodegib works in treating patients with skin basal cell cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, are checkpoint inhibitors that stimulate immune response. Vismodegib may stop the growth of tumor cells by blocking signals needed for cell growth.
NCT02690948 — Skin Basal Cell Carcinoma
Status: Completed
http://inclinicaltrials.com/skin-basal-cell-carcinoma/NCT02690948/
Early Detection of Skin Cancer Using Millimetre-Wave Waveguide Reflectometers
Skin cancer represents a large problem in today's healthcare setting. The majority of cancer diagnoses are attributed to malignant skin diseases including its major types: basal cell carcinoma, squamous cell carcinoma and melanoma. Early diagnoses is critical given early detection of malignant lesions largely increases chances of successful treatment. The current gold standard of diagnosis is histopathological examination of biopsied skin. Biopsies are not only invasive and expensive, they have variable positive predictive value, meaning they may often be preformed unnecessarily. As such, the investigators have developed a skin scanner, which is less bulky and expensive than existing similar technologies, as a tool to evaluate skin lesions prior to determining the need for a biopsy. Their objective is to obtain information in order to validate this skin scanner in the context of its ability to accurately identify basal cell carcinoma skin lesions.
NCT02668614 — Carcinoma, Basal Cell
Status: Completed
http://inclinicaltrials.com/carcinoma-basal-cell/NCT02668614/
Polarization Enhanced Wide Field Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers
The purpose of the study is to evaluate the ability and efficacy of using a polarization-enhanced reflectance and fluorescence imaging device, PERFIS, (see the Device Brochure) for demarcation of nonmelanoma skin cancer margins prior to surgery. PERFIS is a harmless and non-invasive device that has been used to image biological tissue both in vitro and in vivo. In this study it will be used to image nonmelanoma skin cancer lesions prior to surgery. The use of PERFIS will not affect patient care or treatment decisions in any way. No extra tissue will be used for imaging.
NCT02666833 — Carcinoma, Squamous Cell
Status: Enrolling by invitation
http://inclinicaltrials.com/carcinoma-squamous-cell/NCT02666833/
Topical Chemoprevention of Skin Cancer Biomarkers
This research study will test how well one topical medications work to prevent the development of non-melanoma skin cancers by reversing certain biomarkers in the skin. This study is also looking at the optimal dose of a medication in a small number of people. Biomarkers are molecules that are found in the body and inside of cells. Some biomarkers are associated with specific diseases such as skin cancer. In this study, one topical medication will be evaluated; diclofenac. Diclofenac and is approved by the Food and Drug Administration (FDA) for other uses. 24 patients will be enrolled in this study by University of Alabama at Birmingham.
NCT02636569 — Non-melanoma Skin Cancer
Status: Active, not recruiting
http://inclinicaltrials.com/non-melanoma-skin-cancer/NCT02636569/
Association of Viral Reactivation and Skin Cancer in Organ Transplant Recipients
Several studies show that the incidence of skin cancer parallels the length and depth of immunosuppression. This study will analyze the correlation of viral reactivation and skin cancer in organ transplant recipients.
NCT02395562 — Skin Cancer
Status: Completed
http://inclinicaltrials.com/skin-cancer/NCT02395562/
Skin Cancer in Swiss Transplant Cohort Study
It's known that organ transplant recipients with long-term drug-induced immunosuppression have a increase of the life-time incidence of squamous cell carcinoma. This study will analyze the incidence and type of skin cancer in the Swiss Transplant Cohort Study and the association with exposure to immunosuppressive and antiinfective drugs and other parameters like age or gender of organ transplant recipients.
NCT02361229 — Skin Cancer
Status: Active, not recruiting
http://inclinicaltrials.com/skin-cancer/NCT02361229/
Skin Cancer Screening Education Study
The overall aim of this population-based screening study is to assess whether the skin cancer screening training of family physicians and dermatologists leads to improved screening outcomes. The training course aims to increase the accuracy of detecting early stages of skin cancer. Screening outcomes of an intervention region (Calgary, Canada) in which physicians receive training will be compared with screening outcomes of a control region (Edmonton, Canada) where no physician training is administered. The investigators will determine whether: - clinical screening outcomes are more favorable in the group of trained physicians compared to non trained physicians - there is an increase of knowledge about skin cancer screening among trained physicians, compared to non trained physicians - skin cancer screenings are associated with psycho-social harms - population-based screening has an effect on the overall incidence and stage-specific-incidence of skin cancer in Alberta The investigators are aiming to recruit 100 physicians per region (total of 200 physicians) who will screen 40,000 to 80,000 individuals over a period of 20 months.
NCT02352428 — Melanoma
Status: Active, not recruiting
http://inclinicaltrials.com/melanoma/NCT02352428/
Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients
This study is proposed based on our work showing that the diabetes drug Pioglitazone strongly inhibits growth of tissue cultured squamous cell carcinoma (SCC) of the skin. This occurs at concentrations readily achievable by oral administration of this drug using doses currently approved for the treatment of diabetes. In our study, we propose to enroll 40 non-diabetic adult subjects (18-80 yrs of age inclusive) with a documented clinical history of frequent occurrence of skin squamous cell cancer to receive Pioglitazone (Actos®,Takeda Pharmaceuticals). Each subject will receive usual care for all new tumors they develop while on study (i.e, excision and plastic repair). The study protocol will randomize (1:1) patients for 6 months of observation followed by 6 months of treatment (group 1) or 6 months of treatment with drug followed by observation for 6 months (to examine washout effects). The biopsy specimens collected on and off therapy will be examined to determine if they express AKR1C3, an enzyme we believe increases resistance of SCC to prostaglandin inflammatory mediators. We will also examine the histologic grade of the removed tumors and study whether Pioglitazone treatment can decrease the number of aggressive versus well differentiated tumors in study patients. This pilot study is designed to detect a statistically significant change in SCC tumor numbers but is not sponsored by the drug manufacturer. The data obtained will not be used to effect a change in the product label.
NCT02347813 — Squamous Cell Carcinoma of the Skin
Status: Completed
http://inclinicaltrials.com/squamous-cell-carcinoma-of-the-skin/NCT02347813/
A Pilot Study of Neoadjuvant Cetuximab in Advanced Squamous Cell Carcinomas of Skin (SCCS)
This pilot clinical trial studies the side effects and how well cetuximab before surgery works in treating patients with skin cancer that forms, grows, and spreads quickly and has spread from where it started to nearby tissue or lymph nodes. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways be targeting certain cells. Giving cetuximab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
NCT02324608 — Squamous Cell Carcinoma of the Skin
Status: Completed
http://inclinicaltrials.com/squamous-cell-carcinoma-of-the-skin/NCT02324608/